Wacker Chemie AG

  • WKN: WCH888
  • ISIN: DE000WCH8881
  • Land: Deutschland

Nachricht vom 16.06.2021 | 17:10

Wacker Chemie AG: WACKER Raises its Forecast for Fiscal Year 2021

Wacker Chemie AG / Key word(s): Profit Warning/Change in Forecast
Wacker Chemie AG: WACKER Raises its Forecast for Fiscal Year 2021

16-Jun-2021 / 17:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Disclosure of Insider Information as per
Article 17 of MAR

Wacker Chemie AG / Forecast Change

WACKER Raises its Forecast for Fiscal Year 2021

Munich, June 16, 2021, 16.30 p.m. CEST - Following the sustained positive performance of its business, Wacker Chemie AG ("WACKER") is raising its full-year guidance for sales and EBITDA. The company now expects full-year 2021 sales of around €5.5 billion (2020: €4.69 billion). Previously, WACKER had assumed sales growth in the low double-digit percentage range. Group EBITDA for 2021 is expected to be between €900 million and €1.1 billion. Previously, WACKER had expected EBITDA to rise by 15 to 25 percent year-on-year (€666 million). For Q2 2021, WACKER expects sales of around €1.5 billion and EBITDA between €300 million and €350 million.

The ongoing positive development of polysilicon prices and the continuously strong demand in WACKER's chemical business are the reasons for the higher expectations. At the same time, however, higher raw material prices and negative currency effects are expected to weigh on EBITDA with more than €300 million (previous forecast: more than €200 million). The current forecast takes this development into account.

Issuer and Contact

Wacker Chemie AG
Hanns-Seidel-Platz 4
81737 Munich, Germany
Investor Relations
Joerg Hoffmann
Tel. +49 89 6279 1633
Fax: +49 89 6279-1179
investor.relations@wacker.com
www.wacker.com

Additional Information

ISIN: DE000WCH8881
WKN: WCH888
Deutsche Boerse: WCH
Ticker, Bloomberg: CHM/WCH:GR
Ticker, Reuters: CHE/WCHG.DE
Listing: Frankfurt Stock Exchange (Frankfurter Wertpapierbörse), Official Market (Prime Standard)

Disclaimer
This publication contains forward-looking statements based on assumptions and estimates of WACKER's Executive Board. Although we assume the expectations in these forward-looking statements are realistic, we cannot guarantee they will prove to be correct. The assumptions may harbor risks and uncertainties that may cause the actual figures to differ considerably from the forward-looking statements. Factors that may cause such discrepancies include, among other things, changes in the economic and business environment, variations in exchange and interest rates, the introduction of competing products, lack of acceptance for new products or services, and changes in corporate strategy. WACKER does not plan to update its forward-looking statements, nor does it assume the obligation to do so.

This document includes supplemental financial measures (not clearly defined in the applicable financial reporting framework) that are or may be alternative performance measures (APM). These supplemental financial measures should not be viewed in isolation or as alternatives to measures of WACKER's net assets and financial positions or results of operations as presented in accordance with the applicable financial reporting framework in its Consolidated Financial Statements. Other companies that report or describe similarly titled alternative performance measures may calculate them differently. Explanations of financial measures used can be found in the Annual Report 2020 of Wacker Chemie AG which is available for download under www.wacker.com.


16-Jun-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021